BOT

NASDAQU.S. Equity

RoboStrategy

Sponsor: RoboStrategy · Inception May 10, 2026

Market priceShare price

$26.18

-3.71% ($-1.01)

NAVAsset value per share

$7.34

as of Feb 28, 2026 · SEC filing

Premium / discountPrice vs. assets

256.68% premium *

Indicative: latest price vs latest reported NAV

Distribution rate (price)Payout rate

—

regular, annualised · on NAV —

Expense ratioAnnual cost

3.98%

fee table, Aug 24, 2026

LeverageBorrowing

Not reported

senior securities not tagged

Quote status: Market closed — last regular-session price · last trade Oct 15, 2026, 4:00 PM EDT (exchange time, ET) · retrieved Oct 15, 2026, 5:45 PM EDTRegular-session prices; extended-hours quotes are not displayed.

From the wire

News mentioning BOT

16 headlines

U.S. Equity

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of

GuruFocus · Oct 3 · 11:00 UTC ↗

BOT · U.S. Equity

RoboStrategy to Host Robotics Founders Forum and Ring the Nasdaq Closing Bell with Dyna Robotics Humanoid on October 13

GlobeNewsWire · Oct 8 · 16:05 UTC ↗ · BOT · U.S. Equity

RoboStrategy, Inc. Updates Net Asset Value as of September 30, 2026

GlobeNewsWire · Oct 5 · 17:00 UTC ↗ · BOT · U.S. Equity

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

GuruFocus · Oct 2 · 10:00 UTC ↗ · BOT · U.S. Equity

RoboStrategy (BOT) CEO on Autonomous Robot Growth, NVDA & Making AI Investments

Schwab Network · Sep 17 · 20:00 UTC ↗ · BOT · U.S. Equity

RoboStrategy, Inc. Updates Net Asset Value as of August 31, 2026

GlobeNewsWire · Sep 2 · 17:00 UTC ↗ · BOT · U.S. Equity

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

GuruFocus · Aug 28 · 11:00 UTC ↗ · BOT · U.S. Equity

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

GuruFocus · Aug 26 · 11:00 UTC ↗ · BOT · U.S. Equity

RoboStrategy, Inc. Releases First Shareholder Letter

GlobeNewsWire · Aug 24 · 11:30 UTC ↗ · BOT · U.S. Equity

RoboStrategy, Inc. Updates Net Asset Value as of July 31, 2026

GlobeNewsWire · Aug 12 · 08:39 UTC ↗ · BOT · U.S. Equity

RoboStrategy, Inc. Raises Approximately $16.0 Million Through Private Share Issuances, Including $10.0 Million Investment by CEO Andrew Kang

GlobeNewsWire · Jul 15 · 08:56 UTC ↗ · BOT · U.S. Equity

RoboStrategy, Inc. Announces Updated Net Asset Value and Additional Private Placements

GlobeNewsWire · Jul 8 · 08:30 UTC ↗ · BOT · U.S. Equity

RoboStrategy, Inc. Raises Approximately $33.9 Million Through Private Share Issuances

GlobeNewsWire · Jun 29 · 08:40 UTC ↗ · BOT · U.S. Equity

RoboStrategy, Inc. Raises Approximately $36.5 Million Through Private Share Issuances

GlobeNewsWire · Jun 26 · 09:00 UTC ↗ · BOT · U.S. Equity

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

GuruFocus · Jun 25 · 08:00 UTC ↗ · BOT · U.S. Equity

RoboStrategy, Inc. Updates Net Asset Value as of June 22, 2026

GlobeNewsWire · Jun 24 · 09:20 UTC ↗ · BOT · U.S. Equity

Headlines link to the original publisher; the publisher’s own image is shown where the feed supplies one. Syndicated duplicates are collapsed. Activist or governance items are shown as filed positions or proposals, not as inferred intent.

CEF Explorer research page for RoboStrategy, Inc.. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.